New asthma drug shows promise in real-world greek study

NCT ID NCT05440656

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 152 adults in Greece with severe eosinophilic asthma who were starting benralizumab, a medication that helps control severe asthma. Researchers measured not only standard asthma control but also quality of life, sleep, mood, and physical activity using wearable trackers over 48 weeks. The goal was to see how the drug works in routine care beyond just lung function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE EOSINOPHILIC ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma pulmonary eosinophilia T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE EOSINOPHILIC ASTHMA

Contacts and locations

Locations

Research Site

Alexandroupoli, 68100, Greece
Research Site

Athens, 11521, Greece
Research Site

Athens, 11527, Greece
Research Site

Athens, 12462, Greece
Research Site

Athens, 15125, Greece
Research Site

Athens, 17562, Greece
Research Site

Corfu, 49100, Greece
Research Site

Heraklion, 71500, Greece
Research Site

Ioannina, 45500, Greece
Research Site

Rio, 26504, Greece
Research Site

Thessaloniki, 55535, Greece
Research Site

Thessaloniki, 56429, Greece
Research Site

Thessaloniki, 57010, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.